News

Capricor: Maintaining Hold Rating In Light Of Deramiocel Complete Response Letter
Capricor Therapeutics is expected to release data from the phase 3 HOPE-3 trial in Q3'25, thus presenting a potential path ...
Managed Healthcare Executive21h
Capricor’s DMD Cell Therapy Faces FDA Setback
The company said it was optimistic that the issues identified by the Food and Drug Administration could be resolved with new data.
SunStar4h
Student with rare muscle condition shows disability doesn’t mean inability
They said he wouldn’t make it this far. He’s proving them wrong -- one push at a time.” At just 16, Nathan Espina is defying ...
Health and Me on MSN6h
Over 70 Million Indians Affected By Rare Diseases Amid Ongoing Challenges
Over 70 million Indians live with rare diseases, facing challenges like delayed diagnosis, high treatment costs, and limited ...
Investor's Business Daily on MSN19h
Capricor Therapeutics Hammered On A Surprise FDA Rejection
Shares of Capricor TherapeuticsCAPR plummeted Friday after the Food and Drug Administration rejected its experimental ...
BioWorld18h
Capricor gets CRL for cell therapy BLA in rare disease
Capricor Therapeutics Inc. received a complete response letter (CRL) from the U.S. FDA on the BLA for deramiocel to treat cardiomyopathy in Duchenne muscular dystrophy patients. The company’s CEO said ...
Explore more
Solid Biosciences: SGT-003's Safety Profile Illuminates DMD Gene Therapy Path (Rating Upgrade)
Solid Biosciences' DMD gene therapy shows promise with SGT-003 and strong cash backing through 2027. Click here to read an ...
PipelineReview.com4h
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
SAN DIEGO, CA, USA I July 11, 2025 I Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based ...